Defective DNA double strand break response due to BARD1 loss of function

Baer, RJ., Orlic-Milacic, M.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of Creative Commons Attribution 4.0 International (CC BY 4.0) License. For more information see our license.

This is just an excerpt of a full-length report for this pathway. To access the complete report, please download it at the Reactome Textbook.

15/11/2022

https://reactome.org
Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references


Reactome database release: 82

This document contains 1 pathway and 1 reaction (see Table of Contents)
Defective DNA double strand break response due to BARD1 loss of function

Stable identifier: R-HSA-9699150

Diseases: cancer

Although germline mutations of BARD1 are implicated in some cases of hereditary breast and ovarian cancer (HBOC), they occur less frequently that those of the BRCA1 or BRCA2 genes (De Brakeleer et al. 2010, Alenezi et al. 2020). From animal studies, it is known that the loss of BARD1 function results in a phenotype very similar to that caused by loss of BRCA1 function, characterized by embryonic lethality (McCarthy et al. 2003), genomic instability (McCarthy et al. 2003) and defects in homology-directed repair (Lee et al. 2015). A small number of clinically-relevant BARD1 missense mutants that have been functionally characterized and shown to be impaired in BRCA1 binding (Xia et al. 2003, Lee et al. 2015) are annotated in this pathway.

Literature references


## Editions

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020-09-30</td>
<td>Authored</td>
<td>Orlic-Milacic, M.</td>
</tr>
<tr>
<td>2020-11-04</td>
<td>Reviewed</td>
<td>Baer, RJ.</td>
</tr>
<tr>
<td>2020-11-09</td>
<td>Edited</td>
<td>Orlic-Milacic, M.</td>
</tr>
</tbody>
</table>
Defective BARD1 does not bind BRCA1

Location: Defective DNA double strand break response due to BARD1 loss of function

Stable identifier: R-HSA-9699163

Type: transition

Compartments: nucleoplasm

Diseases: cancer

The N-terminal RING domain and C-terminal BRCT repeats of BARD1 contribute to its binding to BRCA1 (Simons et al. 2006). While not frequently reported in cancer, missense mutations in these two regions of BARD1 affect BARD1 function in homology directed repair (HDR) by impairing its interaction with BRCA1 and may potentially contribute to hereditary breast and ovarian cancer (Lee et al. 2015).

The following BARD1 missense mutants have been reported in hereditary breast and ovarian cancer and shown to be impaired in their interaction with BRCA1 and in HDR:

BARD1 C53W (Lee et al. 2015; the C53W substitution produces an insoluble BARD1 protein)

BARD1 C71Y (Morris et al. 2002; Lee et al. 2015; the C71Y substitution produces an insoluble BARD1 protein)

BARD1 G623E (Lee et al. 2015).

The following BARD1 mutants impaired in their ability to bind to BRCA1 have been clinically reported but not in cancer samples and are annotated as candidates:

BARD1 W34R (Lee et al. 2015 - studied as a synthetic mutant, but is in ClinGen Allele Registry, Pawliczek et al. 2018)

BARD1 L44R (Morris et al. 2002, Lee et al. 2015 - studied as a synthetic mutant, but is in ClinGen Allele Registry, Pawliczek et al. 2018)

BARD1 C50G (Xia et al. 2003)

BARD1 C83G (Xia et al. 2003)

The following BARD1 mutants reported in cancer and predicted to be pathogenic have not been tested for their ability to bind to BRCA1 but share sequence similarity with functionally characterized BARD1 mutants:

BARD1 H68Y (similar to functionally characterized synthetic mutant BARD1 H68A, described in Xia et al. 2003)
BARD1 G632W (similar to functionally characterized cancer mutant BARD1 G623E, described in Lee et al. 2015).

**Literature references**


**Editions**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020-09-30</td>
<td>Authored</td>
<td>Orlic-Milacic, M.</td>
</tr>
<tr>
<td>2020-11-04</td>
<td>Reviewed</td>
<td>Baer, RJ.</td>
</tr>
<tr>
<td>2020-11-09</td>
<td>Edited</td>
<td>Orlic-Milacic, M.</td>
</tr>
</tbody>
</table>
Table of Contents

Introduction 1

Defective DNA double strand break response due to BARD1 loss of function 2

Defective BARD1 does not bind BRCA1 4

Table of Contents 6